We serve Chemical Name:2,6-bis(trifluoromethyl)-1H-pyridin-4-one CAS:43150-55-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,6-bis(trifluoromethyl)-1H-pyridin-4-one
CAS.NO:43150-55-6
Synonyms:2,6-Bis-trifluormethyl-4-pyridinol;2,6-bis(trifluoromethyl)-4-hydroxypyridine;2,6-BIS(TRIFLUOROMETHYL)PYRIDIN-4-OL;2,6-di(trifluoromethyl)-4-hydroxypyridine;2,6-Bis(trifluoromethyl)-4-pyridinol;4-Pyridinol 2,6-bis[trifluoromethyl]
Molecular Formula:C7H3F6NO
Molecular Weight:231.09500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:33.12000
Exact Mass:231.01200
LogP:2.82480
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,6-Bis-trifluormethyl-4-pyridinol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Pyridinol 2,6-bis[trifluoromethyl] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,6-Bis-trifluormethyl-4-pyridinol Use and application,2,6-di(trifluoromethyl)-4-hydroxypyridine technical grade,usp/ep/jp grade.
Related News: The additional GMP labs will be able to develop and manufacture highly potent API (HPAPI) under GMP standards. The expanded labs and manufacturing facilities are expected to come online between 1Q22 and 3Q22. Pyridinium, 1,1′-(1,3-propanediyl)bis[4-phenyl-, dibromide manufacturers The group of diseases known as severe combined immunodeficiency, or SCID, first drew wide attention decades ago because of David Vetter, a boy born with X-linked SCID who lived in a bubble for 12 years as doctors tried to figure out how to cure him. 3-(2-dimethylamino-ethyl)-3-aza-bicyclo[3.2.0]heptane-2,4-dione suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. N-methyl-N-(3-(piperidin-1-yl)propyl)benzo[c][1,2,5]oxadiazole-4-sulfonamide vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. N-methyl-N-(3-(piperidin-1-yl)propyl)benzo[c][1,2,5]oxadiazole-4-sulfonamide vendor & factory.
